Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

748.71 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

58 59 Next >

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗

October 04, 2023

Via Benzinga

MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer ↗

October 03, 2023

MAIA Biotechnology, Inc. (AMEX: MAIA) announced that the U.S.

Via Benzinga

Regeneron Pharmaceuticals Unusual Options Activity ↗

October 03, 2023

Via Benzinga

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

October 03, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 02, 2023

Via Benzinga

Examining the Quality Attributes of NASDAQ:REGN. ↗

September 22, 2023

Why the quality investor may take a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN).

Via Chartmill

Analyst Expectations for Regeneron Pharmaceuticals's Future ↗

September 21, 2023

Via Benzinga

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/19 Morning Trading

September 19, 2023

Via Investor Brand Network

Stock Split Watch: Is Regeneron Pharmaceuticals Next? ↗

September 30, 2023

If the biotech does split its stock, it will be a first for the company.

Via The Motley Fool

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

September 29, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

September 28, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 28, 2023

Via Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗

September 18, 2023

Via Benzinga

Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗

September 14, 2023

Via Benzinga

Check Out What Whales Are Doing With REGN ↗

September 08, 2023

Via Benzinga

Three Of Our Top Picks For Your Healthcare Portfolio ↗

September 26, 2023

Amidst macro uncertainty, healthcare stocks should outperform.

Via Talk Markets

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

September 26, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

September 25, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/8 Morning Trading

September 08, 2023

Via Investor Brand Network

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost ↗

September 20, 2023

A higher-dose version of Eylea will help the company fight off competition and increase revenue.

Via The Motley Fool

3 Stocks to Buy to Ride Europe’s Coming Market Surge ↗

September 19, 2023

With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave.

Via InvestorPlace

AI Integration In Biotech & Pharma: Companies Positioned To Benefit ↗

September 11, 2023

The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care....

Via Benzinga

Topics Artificial Intelligence

Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023 ↗

September 15, 2023

Via Benzinga

New to Investing? Here's How You Can Get Started With $500. ↗

September 10, 2023

You don't have to invest a lot to start building a winning portfolio.

Via The Motley Fool

3 Unstoppable Growth Stocks to Buy Right Now ↗

September 09, 2023

These healthcare stocks show no signs of slowing down.

Via The Motley Fool

Regeneron Provides Update on Planned Chief Financial Officer Transition

September 08, 2023

Robert E. Landry to retire effective February 2024; Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO role

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Announces Updates to Board of Directors

September 08, 2023

Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron’s Board of Directors

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Top Biotech Stocks to Buy in September ↗

September 08, 2023

There is rarely a bad time to buy stocks with massive upside potential.

Via The Motley Fool

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

All News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today